All In Biotech

Drug Trial Radar · NCT00003752

Bexarotene in Treating Patients With Metastatic Breast Cancer

A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer

Last checked: Nov 20, 2026Latest source record: May 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Planned (sponsor's estimate)

Start

Oct 1998

Primary completion

Not stated

Study completion Mar 2003

Sponsor

Lead sponsor
Ligand PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 25, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • bexaroteneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Comprehensive Cancer Center

    Birmingham, Alabama

  • Arizona Cancer Center

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Jonsson Comprehensive Cancer Center, UCLA

    Los Angeles, California

  • Beckman Research Institute, City of Hope

    Los Angeles, California

  • Kaiser Permanente-Southern California Permanente Medical Group

    San Diego, California

  • UCSF Cancer Center and Cancer Research Institute

    San Francisco, California

  • Yale Comprehensive Cancer Center

    New Haven, Connecticut

  • Vincent T. Lombardi Cancer Research Center, Georgetown University

    Washington D.C., District of Columbia

  • Baptist Regional Cancer Institute - Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Sylvester Cancer Center, University of Miami

    Miami, Florida

  • Cancer Research Center of Hawaii

    Honolulu, Hawaii

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University

    Chicago, Illinois

  • Louisiana State University School of Medicine

    New Orleans, Louisiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Michigan State University

    East Lansing, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Arthur G. James Cancer Hospital - Ohio State University

    Columbus, Ohio

  • Hematology Oncology Consultants Inc

    Columbus, Ohio

  • Oregon Cancer Center at Oregon Health Sciences University

    Portland, Oregon

  • University of Pennsylvania Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon-Minnie Pearl Cancer Center

    Nashville, Tennessee

  • University of Texas - MD Anderson Cancer Center

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Cancer Center, University of Virginia HSC

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.